Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerPolicy UpdatesPreventive Services & ScreeningBlue Cross Blue Shield NC FIT‑DNA Coverage Update …
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - North CarolinaPolicy N/A

    Colorectal cancer screening with stool DNA (FIT‑DNA/Cologuard)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - North Carolina policy alerts

    Know when Blue Cross Blue Shield - North Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines BCBSNC coverage and reimbursement policy for colorectal cancer screening using DNA analysis of stool samples for average‑risk, asymptomatic adults and related billing guidance for providers.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyColorectal cancer screening with stool DNA (FIT‑DNA/Cologuard)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateApr 1, 2025
    Key ActionVerify benefits and eligibility and bill CPT 81528 when submitting claims for FIT‑DNA (Cologuard); inclusion of the code does not guarantee reimbursement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    every 3 yearsallowed screening interval

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    avg risk ≥45
    recommended population
    81528applicable CPT
    <3 yearsdenied if...

    Coverage Criteria

    Covered screening criteria

    Covered when ALL of the following are met

    Population: Asymptomatic individuals at average risk for colorectal canceraligned with USPSTF definition (no prior CRC, adenomatous polyps, inflammatory bowel disease, or known high‑risk hereditary colorectal cancer syndromes)

    see USPSTF referenced in policy

    Test interval: FIT‑DNA (stool DNA) testing is allowed only every 3 yearsinterval = 3 years

    Policy allows reimbursement every 3 years; testing at intervals shorter than 3 years is not reimbursed

    Purpose: Test is used as a screening technique (not for diagnostic evaluation or surveillance in high‑risk individuals)screening indication only

    Positive FIT‑DNA results should be followed by diagnostic colonoscopy

    Reimbursement is not allowed for colorectal cancer screening using DNA analysis of stool samples when performed for indications other than average‑risk screening. This includes use for diagnostic evaluation, surveillance of known colorectal cancer or adenomatous polyps, inflammatory bowel disease, or any other non–average‑risk purpose.

    Reimbursement is not allowed for screening with DNA analysis of stool samples when performed at an interval of less than 3 years.

    Use of stool DNA testing for indications other than average‑risk screening or at intervals shorter than 3 years is considered not covered and reimbursement will not be allowed.

    Coding and Billing Codes

    Applicable service codesCPTCovered
    81528Oncology (colorectal) screening, quantitative real-time target and signal amplification of 10 DNA markers and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result.

    Provider Actions and Billing Guidance

    Billing Rule

    Billing code guidance — CPT 81528

    Use CPT code 81528 when billing for FIT‑DNA (Cologuard); inclusion in the policy’s billing/coding section does not guarantee reimbursement — verify member benefits and eligibility per BCBSNC reimbursement rules.

    • Applicable service code listed: 81528
    • Inclusion of a code does not guarantee it will be reimbursed; consult BCBSNC administrative reimbursement guidance
    Note

    Document screening indication and test interval

    Ensure claims and documentation explicitly state the screening indication and that the member is average risk; BCBSNC may request supporting records to confirm the indication and interval.

    • Document that the individual is asymptomatic and meets the policy definition of average risk.

    Definitions

    FIT‑DNA / Cologuard (81528) — definition and markers
    Test name (CPT)FIT‑DNA / Cologuard — CPT 81528
    Assay componentsCombination of fecal immunochemical test (fecal hemoglobin) plus stool DNA analysis detecting multiple DNA markers (eg, KRAS mutations; promoter methylation of NDRG4 and BMP3)
    Result formatAlgorithm reported as a positive or negative qualitative result
    Intended useScreening for colorectal neoplasia (detects DNA markers and occult hemoglobin in stool); positive results should be followed by diagnostic colonoscopy
    Average risk — definition of average risk population
    DefinitionNo prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal or family history of genetic disorders that confer high lifetime CRC risk (eg, Lynch syndrome, familial adenomatous polyposis)

    Background

    Colorectal cancers and advanced precursors shed DNA into stool, and combined fecal immunochemical plus stool DNA assays were developed to detect these markers. However, this policy limits coverage to average‑risk screening at the recommended interval; other uses or more frequent testing are excluded from reimbursement.

    Policy Summary
    PayerBlue Cross Blue Shield - North Carolina
    PolicyColorectal cancer screening with stool DNA (FIT‑DNA/Cologuard)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateApr 1, 2025
    Last ReviewApr 1, 2025
    Next Review DateApr 1, 2025
    Key ActionVerify benefits and eligibility and bill CPT 81528 when submitting claims for FIT‑DNA (Cologuard); inclusion of the code does not guarantee reimbursement.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Billing CodesProvider Actions and Billing GuidanceDefinitionsBackground
  1. Document the date of prior FIT‑DNA testing to confirm the 3‑year interval between tests.
  2. Documentation Required

    Provide full medical records when requested

    Follow BCBSNC requirements for documentation and medical-necessity determinations; include all requested records and any letters of support only when they contain the specific information needed to make the determination.

    • BCBSNC may request medical records for determination of medical necessity.
    • Letters of support/explanation are not sufficient unless they include all specific information needed for the medical necessity determination.
    Denial Risk

    Denial risk — testing interval < 3 years

    Do not bill or expect reimbursement for FIT‑DNA screening performed more frequently than every 3 years; tests at intervals less than 3 years are not reimbursed.

    • Reimbursement is not allowed for screening with DNA analysis of stool samples at an interval of less than 3 years.
    Denial Risk

    Non‑covered indications — not average‑risk screening

    Do not submit claims for FIT‑DNA (stool DNA) testing for indications other than average‑risk colorectal cancer screening; such uses are not covered and will be denied.

    • Reimbursement is not allowed for colorectal cancer screening with DNA analysis of stool samples for all other indications (i.e., indications other than average‑risk screening).
    Population referencedAsymptomatic adults beginning at age 45 (USPSTF recommendation)
    Exclusions (examples)Individuals with prior CRC, adenomatous polyps, IBD, or known high‑risk hereditary CRC syndromes are not considered average risk